# **Special Issue**

# EVs and EPS in Cancer: Cell-to-Cell Communication, Diagnosis, and Evaluation of Cancer Therapy Response

## Message from the Guest Editors

Extracellular vesicles (EVs) and Particles (EPs) play essential roles in intercellular signaling in cancers. Interest in EVs increased dramatically after the discovery that EVs could transfer nucleic acids like RNA from cell to cell. Associated with EVs from certain cells or tissues, nucleic acids could be easily amplified as markers of tumor cells. When EVs are taken up by other cells, they may alter the behavior of the recipient cell. Thus, EVs are of importance in forming tumor landscapes.

This Special Issue is aimed at understanding not only EV-based cell-to-cell communication in cancers but also EVs and EPs in the diagnosis of cancers and evaluation of the therapy response. Topics of interest may range from the application of EVs in liquid biopsy to the latest technology and discovery of EVs to characterize cancer cells. Original research papers and review articles in related fields are welcomed.

#### **Guest Editors**

Prof. Dr. Irina Nazarenko

Institute for Infection Prevention and Hospital Epidemiology, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

Dr. José Antonio López-Guerrero

Head of the Laboratory of Molecular Biology Scientific Manager of the Biobank, Fundación Instituto Valenciano de Oncología, C/Prof. Beltrán Báguena, 8-11, 46009 Valencia, Spain

#### Deadline for manuscript submissions

closed (20 July 2025)



# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/182953

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

